CIK 1802528
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 12 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DMRA | Damora Therapeutics, Inc. | Health Care | 16.30% |
| 2 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 15.38% |
| 3 | COGT | Cogent Biosciences, Inc. | Health Care | 15.30% |
| 4 | SYRE | Spyre Therapeutics, Inc. | Health Care | 14.64% |
| 5 | ORKA | Oruka Therapeutics, Inc. | Health Care | 13.13% |
| 6 | VRDN | Viridian Therapeutics, Inc.\DE | Health Care | 5.53% |
| 7 | ELVN | Enliven Therapeutics, Inc. | Health Care | 5.25% |
| 8 | JBIO | Jade Biosciences, Inc. | Health Care | 4.62% |
| 9 | CBIO | CRESCENT BIOPHARMA, INC. | Health Care | 3.65% |
| 10 | ZBIO | Zenas BioPharma, Inc. | Health Care | 3.33% |
12/12 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/12 names) · unclassified 100.0%: DMRA, DNTH, COGT, SYRE, ORKA, VRDN, ELVN, JBIO, CBIO, ZBIO +2 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DMRADAMORA THERAPEUTICS INC | 8,713,000 | $226M | 16.3% | NEW |
| 2 | DNTHDIANTHUS THERAPEUTICS INC | 2,537,191 | $213M | 15.4% | ADD 19% |
| 3 | COGTCOGENT BIOSCIENCES INC | 5,503,418 | $212M | 15.3% | TRIM −39% |
| 4 | SYRESPYRE THERAPEUTICS INC | 4,018,101 | $203M | 14.6% | HOLD |
| 5 | ORKAORUKA THERAPEUTICS INC | 3,705,262 | $182M | 13.1% | HOLD |
| 6 | VRDNVIRIDIAN THERAPEUTICS INC | 3,914,458 | $77M | 5.5% | HOLD |
| 7 | ELVNENLIVEN THERAPEUTICS INC | 1,855,644 | $73M | 5.3% | TRIM −50% |
| 8 | JBIOJADE BIOSCIENCES INC | 4,553,494 | $64M | 4.6% | HOLD |
| 9 | CBIOCRESCENT BIOPHARMA INC. | 2,747,866 | $50M | 3.6% | HOLD |
| 10 | ZBIOZENAS BIOPHARMA INC | 2,359,025 | $46M | 3.3% | ADD 7% |
| 11 | APGEAPOGEE THERAPEUTICS INC | 298,647 | $25M | 1.8% | TRIM −85% |
| 12 | IKTINHIBIKASE THERAPEUTICS INC | 8,625,000 | $14M | 1.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DMRADAMORA THERAPEUTICS INC | — | — | — | — | — | 8.7M | $226M |
| DNTHDIANTHUS THERAPEUTICS INC | 2.7M | 2.7M | 2.7M | 3.3M | 2.1M | 2.5M | $213M |
| COGTCOGENT BIOSCIENCES INC | 6.2M | 6.2M | 6.2M | 9.0M | 9.0M | 5.5M | $212M |
| SYRESPYRE THERAPEUTICS INC | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | $203M |
| ORKAORUKA THERAPEUTICS INC | 3.4M | 3.4M | 3.4M | 3.7M | 3.7M | 3.7M | $182M |
| VRDNVIRIDIAN THERAPEUTICS INC | 3.4M | 3.4M | 3.5M | 3.5M | 3.9M | 3.9M | $77M |
| ELVNENLIVEN THERAPEUTICS INC | 3.2M | 3.2M | 3.7M | 3.7M | 3.7M | 1.9M | $73M |
| JBIOJADE BIOSCIENCES INC | — | — | 3.2M | 3.2M | 4.6M | 4.6M | $64M |
| CBIOCRESCENT BIOPHARMA INC. | — | — | 1.4M | 1.4M | 2.7M | 2.7M | $50M |
| ZBIOZENAS BIOPHARMA INC | 1.9M | 1.9M | 1.9M | 1.9M | 2.2M | 2.4M | $46M |
| APGEAPOGEE THERAPEUTICS INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 299K | $25M |
| IKTINHIBIKASE THERAPEUTICS INC | 6.1M | 6.1M | 6.1M | 6.1M | 8.6M | 8.6M | $14M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
